Hong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hong Sun has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jingchao Yan
Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China
4 shared publications - Taomin Huang
Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China
4 shared publications Xiu Xin
Department of Pharmacy Eye & ENT Hospital, Fudan University Shanghai China
4 shared publicationsFengjiao Bu
Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China
3 shared publicationsJingchao Yan
Department of Pharmacy Eye & ENT Hospital, Fudan University Shanghai China
2 shared publicationsLing Li
Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- 21 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11689-11701
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon‐Like Peptide‐1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for Type 2 diabetes (T2DM) and obesity, but emerging evidence links them to nonarteritic anterior ischemic optic neuropathy (NAION). Whether this risk differs across agents and the underlying mechanisms remains unclear. We aimed to compare the risks of NAION associated with different GLP‐1RAs and to explore the potential molecular mechanisms underlying this adverse reaction. Materials and Methods: A network meta‐analysis was performed to quantitatively compare the differences in NAION risk. Real‐world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) were used for validation. Network toxicology was further applied to identify central hub targets and signalling pathways. Molecular docking was conducted to evaluate the binding capacity of GLP‐1RAs to central hub targets. Results: The network meta‐analysis revealed significant differences in NAION risk across GLP‐1RAs. Compared with non‐GLP‐1RA treatments, semaglutide showed the highest risk (HR = 1.538, 95% CI: 1.305–1.816), followed by liraglutide (HR = 1.251, 95% CI: 1.080–1.450). FAERS pharmacovigilance analysis suggested a strong disproportionate signal for semaglutide (ROR = 94.534, 95% CI: 83.093–107.552) and a statistically significant but weaker signal for liraglutide (ROR = 4.519, 95% CI: 2.617–7.802). Network toxicology identified CASP3 as the central hub target, and pathway enrichment analysis revealed that the underlying mechanisms were primarily related to Alzheimer's disease, neurodegeneration pathways, and lipid and atherosclerosis pathways. Molecular docking suggested that semaglutide and liraglutide had high binding affinity to CASP3. Conclusions: The combined strategy of network meta‐analysis, pharmacovigilance, network toxicology and molecular docking provides insights into possible risk differences and potential mechanisms, and may guide future research on the safety profile of GLP‐1RAs.
- 21 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11689-11701
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon‐Like Peptide‐1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for Type 2 diabetes (T2DM) and obesity, but emerging evidence links them to nonarteritic anterior ischemic optic neuropathy (NAION). Whether this risk differs across agents and the underlying mechanisms remains unclear. We aimed to compare the risks of NAION associated with different GLP‐1RAs and to explore the potential molecular mechanisms underlying this adverse reaction. Materials and Methods: A network meta‐analysis was performed to quantitatively compare the differences in NAION risk. Real‐world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) were used for validation. Network toxicology was further applied to identify central hub targets and signalling pathways. Molecular docking was conducted to evaluate the binding capacity of GLP‐1RAs to central hub targets. Results: The network meta‐analysis revealed significant differences in NAION risk across GLP‐1RAs. Compared with non‐GLP‐1RA treatments, semaglutide showed the highest risk (HR = 1.538, 95% CI: 1.305–1.816), followed by liraglutide (HR = 1.251, 95% CI: 1.080–1.450). FAERS pharmacovigilance analysis suggested a strong disproportionate signal for semaglutide (ROR = 94.534, 95% CI: 83.093–107.552) and a statistically significant but weaker signal for liraglutide (ROR = 4.519, 95% CI: 2.617–7.802). Network toxicology identified CASP3 as the central hub target, and pathway enrichment analysis revealed that the underlying mechanisms were primarily related to Alzheimer's disease, neurodegeneration pathways, and lipid and atherosclerosis pathways. Molecular docking suggested that semaglutide and liraglutide had high binding affinity to CASP3. Conclusions: The combined strategy of network meta‐analysis, pharmacovigilance, network toxicology and molecular docking provides insights into possible risk differences and potential mechanisms, and may guide future research on the safety profile of GLP‐1RAs.
- 1 June 2026
- Published by Springer Nature in Eye
- Vol. 40 (11) , 1-9
Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study
Objectives To identify drug-associated risk signals for neovascular age-related macular degeneration (nAMD) and explore their biological basis. Methods We analysed the US FDA Adverse Event Reporting System (FAERS) to detect drugs with disproportionate nAMD reporting. Drug targets were mapped and causality was assessed by integrating summary-based Mendelian randomisation (SMR) and colocalisation analyses using cis-pQTL data. Single-cell RNA sequencing from nAMD patients evaluated cell type-specific gene expression. Protein-protein interaction and pathway enrichment analyses elucidated underlying mechanisms. Results FAERS analysis identified five drugs (apixaban, carbamazepine, latanoprost, rituximab and semaglutide) significantly associated with higher reporting risks of nAMD. SMR implicated six genes (IGFBP6, MAPKAPK2, NFKB1, RGMA, RNASE1 and WARS1) in nAMD risk, with evidence supporting colocalisation for WARS1. Most candidate genes were predominantly expressed in vascular remodelling endothelial cells, while WARS1 was also highly specific to monocytes. Enrichment analysis highlighted their critical involvement in immune and inflammatory responses, particularly within the Toll-like receptor, TNF and NF-kappa B signalling pathways. Conclusions This study suggests a potential association between specific drugs and nAMD and reveals six genes as their possible molecular basis, thereby providing prioritised candidate targets and testable biological hypotheses for subsequent experimental validation.
- 1 June 2026
- Published by Springer Nature in Eye
- Vol. 40 (11) , 1-9
Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study
Objectives To identify drug-associated risk signals for neovascular age-related macular degeneration (nAMD) and explore their biological basis. Methods We analysed the US FDA Adverse Event Reporting System (FAERS) to detect drugs with disproportionate nAMD reporting. Drug targets were mapped and causality was assessed by integrating summary-based Mendelian randomisation (SMR) and colocalisation analyses using cis-pQTL data. Single-cell RNA sequencing from nAMD patients evaluated cell type-specific gene expression. Protein-protein interaction and pathway enrichment analyses elucidated underlying mechanisms. Results FAERS analysis identified five drugs (apixaban, carbamazepine, latanoprost, rituximab and semaglutide) significantly associated with higher reporting risks of nAMD. SMR implicated six genes (IGFBP6, MAPKAPK2, NFKB1, RGMA, RNASE1 and WARS1) in nAMD risk, with evidence supporting colocalisation for WARS1. Most candidate genes were predominantly expressed in vascular remodelling endothelial cells, while WARS1 was also highly specific to monocytes. Enrichment analysis highlighted their critical involvement in immune and inflammatory responses, particularly within the Toll-like receptor, TNF and NF-kappa B signalling pathways. Conclusions This study suggests a potential association between specific drugs and nAMD and reveals six genes as their possible molecular basis, thereby providing prioritised candidate targets and testable biological hypotheses for subsequent experimental validation.
- 11 September 2024
- Published by Springer Nature in Eye
- Vol. 38 (18) , 3473-3480
Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials
Objectives To compare the 2-year efficacy and safety of various anti-vascular endothelial growth factor (VEGF) regimens for neovascular age-related macular degeneration (nAMD). Methods A comprehensive search was performed on multiple electronic databases up to April 2023 and updated in June 2024, to identify relevant randomized controlled trials (RCTs). Key outcomes included the proportion of patients achieving a vision gain of ≥15 letters and maintaining stable vision (loss of <15 letters) in best-corrected visual acuity (BCVA), changes in mean BCVA from baseline, serious ocular adverse events (SAEs), adverse events leading to treatment discontinuation and any cause of death at 2 years. Results Nineteen trials with 12,654 patients and 25 treatment regimens were analyzed in the study. All anti-VEGF regimens showed superior efficacy compared to sham therapy. Specifically, faricimab 6 mg (4+up to Q16W) and ranibizumab 0.5 mg (2-week T&E) displayed top-level effect in vision gain. Bevacizumab 1.25 mg (2-week T&E) and aflibercept 2 mg (2-week T&E) demonstrated the most stable vision outcomes. Bevacizumab 1.25 mg (2-week T&E) and ranibizumab 0.5 mg (2-week T&E) exhibited the most pronounced mean BCVA improvement. Compared to sham therapy, the risk of SAEs was significantly higher for brolucizumab 6 mg (3 + Q12W/ Q8W) (RR = 6.04, 95% CI: 1.30–28.02) and PDS 100 mg/ml (Q24W) (RR = 10.95, 95% CI: 2.14–56.02), but not for other anti-VEGF regimens. Conclusions Ranibizumab 0.5 mg (2-week T&E) emerges as a potentially optimal regimen for nAMD over a 2-year period. Future studies need to consider the impact of baseline characteristics on treatment outcomes.
- 11 September 2024
- Published by Springer Nature in Eye
- Vol. 38 (18) , 3473-3480
Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials
Objectives To compare the 2-year efficacy and safety of various anti-vascular endothelial growth factor (VEGF) regimens for neovascular age-related macular degeneration (nAMD). Methods A comprehensive search was performed on multiple electronic databases up to April 2023 and updated in June 2024, to identify relevant randomized controlled trials (RCTs). Key outcomes included the proportion of patients achieving a vision gain of ≥15 letters and maintaining stable vision (loss of <15 letters) in best-corrected visual acuity (BCVA), changes in mean BCVA from baseline, serious ocular adverse events (SAEs), adverse events leading to treatment discontinuation and any cause of death at 2 years. Results Nineteen trials with 12,654 patients and 25 treatment regimens were analyzed in the study. All anti-VEGF regimens showed superior efficacy compared to sham therapy. Specifically, faricimab 6 mg (4+up to Q16W) and ranibizumab 0.5 mg (2-week T&E) displayed top-level effect in vision gain. Bevacizumab 1.25 mg (2-week T&E) and aflibercept 2 mg (2-week T&E) demonstrated the most stable vision outcomes. Bevacizumab 1.25 mg (2-week T&E) and ranibizumab 0.5 mg (2-week T&E) exhibited the most pronounced mean BCVA improvement. Compared to sham therapy, the risk of SAEs was significantly higher for brolucizumab 6 mg (3 + Q12W/ Q8W) (RR = 6.04, 95% CI: 1.30–28.02) and PDS 100 mg/ml (Q24W) (RR = 10.95, 95% CI: 2.14–56.02), but not for other anti-VEGF regimens. Conclusions Ranibizumab 0.5 mg (2-week T&E) emerges as a potentially optimal regimen for nAMD over a 2-year period. Future studies need to consider the impact of baseline characteristics on treatment outcomes.
- 31 May 2024
- Published by Elsevier in Journal of Affective Disorders
- Vol. 360, 214-220
Association and mechanism of montelukast on depression: A combination of clinical and network pharmacology study
- 31 May 2024
- Published by Elsevier in Journal of Affective Disorders
- Vol. 360, 214-220
Association and mechanism of montelukast on depression: A combination of clinical and network pharmacology study
- 24 April 2024
- Published by Elsevier in Journal of Affective Disorders
- Vol. 356, 728-736
Leukotriene-modifying agents may increase the risk of depression: A cross-sectional study
- 24 April 2024
- Published by Elsevier in Journal of Affective Disorders
- Vol. 356, 728-736
Leukotriene-modifying agents may increase the risk of depression: A cross-sectional study
- 24 July 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (4) , 349-359
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials
Background: Different clinical trials for recurrent or metastatic nasopharyngeal carcinoma have studied different combinations of immuno-oncology in first-line treatment, but the optimal choice has not been determined. Objective: To systematically examine and compare the efficacy and safety of different immune checkpoint inhibitors (ICIs) combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Methods: Several electronic databases were systematically searched up to February 2023. Articles meeting the inclusion criteria were included. Results: Three RCTs were eligible in the study. Compared with placebo plus gemcitabine-cisplatin (GP), toripalimab plus GP (HR = 0.59, 95% CI: 0.37-0.95) was significantly associated with a better OS. Tislelizumab plus GP generated best progression-free survival (PFS) benefit (HR = 0.50, 95% CI: 0.37-0.67), greatest improvement in 1-year PFS rate (RR = 3.00, 95% CI: 1.84-5.22), and objective response rate (ORR) (RR = 1.26, 95% CI: 1.04-1.53) over the placebo plus GP. Furthermore, tislelizumab plus GP appeared to be safer than toripalimab plus GP and camrelizumab plus GP in terms of adverse events (AEs)-grade ≥3, treatment-related AEs (TRAEs)-grade ≥3, serious AEs (SAEs), treatment-related SAEs (TRSAEs), and AEs leading to discontinuation of treatment. Conclusion and Relevance: In recurrent or metastatic nasopharyngeal carcinoma, programmed death 1 (PD-1) inhibitors plus GP as first-line treatment have better survival outcomes than placebo plus GP with comparable toxicity. Toripalimab plus GP shows the best OS benefit over placebo plus GP, while tislelizumab plus GP generates the best PFS, 1-year PFS rate, ORR, and safety. Tislelizumab plus GP could be the best choice among the ICIs combined with chemotherapy regimens as first-line treatment in recurrent or metastatic nasopharyngeal carcinoma.
- 24 July 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (4) , 349-359
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials
Background: Different clinical trials for recurrent or metastatic nasopharyngeal carcinoma have studied different combinations of immuno-oncology in first-line treatment, but the optimal choice has not been determined. Objective: To systematically examine and compare the efficacy and safety of different immune checkpoint inhibitors (ICIs) combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Methods: Several electronic databases were systematically searched up to February 2023. Articles meeting the inclusion criteria were included. Results: Three RCTs were eligible in the study. Compared with placebo plus gemcitabine-cisplatin (GP), toripalimab plus GP (HR = 0.59, 95% CI: 0.37-0.95) was significantly associated with a better OS. Tislelizumab plus GP generated best progression-free survival (PFS) benefit (HR = 0.50, 95% CI: 0.37-0.67), greatest improvement in 1-year PFS rate (RR = 3.00, 95% CI: 1.84-5.22), and objective response rate (ORR) (RR = 1.26, 95% CI: 1.04-1.53) over the placebo plus GP. Furthermore, tislelizumab plus GP appeared to be safer than toripalimab plus GP and camrelizumab plus GP in terms of adverse events (AEs)-grade ≥3, treatment-related AEs (TRAEs)-grade ≥3, serious AEs (SAEs), treatment-related SAEs (TRSAEs), and AEs leading to discontinuation of treatment. Conclusion and Relevance: In recurrent or metastatic nasopharyngeal carcinoma, programmed death 1 (PD-1) inhibitors plus GP as first-line treatment have better survival outcomes than placebo plus GP with comparable toxicity. Toripalimab plus GP shows the best OS benefit over placebo plus GP, while tislelizumab plus GP generates the best PFS, 1-year PFS rate, ORR, and safety. Tislelizumab plus GP could be the best choice among the ICIs combined with chemotherapy regimens as first-line treatment in recurrent or metastatic nasopharyngeal carcinoma.
- Open Access
- 12 February 2020
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 36 (6) , 417-422
Overexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling
It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.
- 12 February 2020
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 36 (6) , 417-422
Open AccessOverexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling
It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.